Table 2.

Effects of chronic TGF-β2 in volume-replete ratsa

VariableVehicle (n = 6)Low Dose (20 μg/kg) (n = 10)Medium Dose (100 μg/kg) (n = 10)
aValues are means ± SEM. SBP, systolic blood pressure; Uprot V, 24-h urinary protein excretion; UNAG V, 24-h urinary excretion of N-acetyl-β-glucosaminidase; UAAP V, 24-h urinary excretion of alanine aminopeptidase. 1 = initial; 2 = final (9 wk for first three groups; 6 wk for 400 μg/kg group). There were no significant differences between changes in the low- and medium-dose groups.
bP < 0.05 versus initial value in same group.
cP < 0.05 versus vehicle.
dP < 0.05 versus low dose.
eP < 0.05 versus change in vehicle group.
BW1 (g)324 ± 6332 ± 6313 ± 5
BW2 (g)457 ± 31b442 ± 12b380 ± 14b,c,d
Change in BW (g)134 ± 26b110 ± 13b67 ± 10b,e
LKW (g)1.29 ± 0.101.33 ± 0.071.23 ± 0.04
LKW/100 g BW0.28 ± 0.010.30 ± 0.010.33 ± 0.01c
SBP1 (mmHg)130 ± 7119 ± 8112 ± 3
SBP2 (mmHg)113 ± 8122 ± 3127 ± 5
Change in SBP (mmHg)-13 ± 7+10 ± 8+16 ± 5b,e
Uprot V1 (mg/d)8 ± 15 ± 110 ± 4
Uprot V2 (mg/d)9 ± 17 ± 19 ± 2
Change in Uprot V (mg/d)2 ± 13 ± 1b2 ± 1
UNAG V1 (U/d)1.8 ± 0.52.1 ± 0.21.7 ± 0.3
UNAG V2 (U/d)2.1 ± 0.31.7 ± 0.21.2 ± 0.3
Change in UNAG V (U/d)0.3 ± 0.3-0.3 ± 0.3-0.5 ± 0.4
UAAP V1 (U/d)2.9 ± 0.73.2 ± 0.62.8 ± 0.3
UAAP V2 (U/d)5.3 ± 0.7b4.3 ± 0.43.0 ± 0.7
Change in UAAP V2 (U/d)2.8 ± 0.31.2 ± 0.70.5 ± 0.9
PRC (ng AngI/ml per h)25 ± 725 ± 423 ± 3
Plasma AngII (fmol/ml)13 ± 47 ± 210 ± 2
Renal AngII (fmol/g)73 ± 2364 ± 1795 ± 12